Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and PD Biosimilarity of Insulin Aspart 30 Injections in Healthy Volunteers
NCT07875803Not yet recruiting
- Sponsor
- The United Laboratories International Holdings
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of insulin aspart in diabetes mellitus (DM) (2 arms), sponsored by The United Laboratories International Holdings. Primary endpoints: Area Under the Curve of Insulin Aspart Plasma Concentration From Time 0 to τ, Peak Plasma Concentration of Insulin Aspart and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07875803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875803.